Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07658677 | Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial | not yet recruiting | Phase 1 / Phase 2 | 50 | Theodore Brasky PhDOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07661797 | Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 294 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT04503278 | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | active not recruiting | Phase 1 | 214 | BioNTech Cell & Gene Therapies GmbHINDUSTRY | 4 | Jun 18, 2026 | clinicaltrials |
| NCT05694715 | Combination Therapy in Cancers With Mutations in DNA Repair Genes | recruiting | Phase 1 | 24 | University of California, San FranciscoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06035744 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 23 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT06992713 | A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656116 | Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors | recruiting | Phase 1 | 27 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657585 | CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors | not yet recruiting | Phase 1 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02862275 | Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | active not recruiting | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04317105 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN | active not recruiting | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06636435 | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | recruiting | Phase 1 | 66 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05159388 | A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | Servier Bio-Innovation LLCINDUSTRY | 4 | Jun 16, 2026 | clinicaltrials |
| NCT06297525 | Study of STP938 (Dencatistat) in Advanced Solid Tumours | recruiting | Phase 1 | 70 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649200 | Study of SNH-118110 in Advanced Solid Tumors(SNH-118110) | not yet recruiting | Phase 1 | 240 | ScinnoHub Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650357 | A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | not yet recruiting | Phase 1 | 140 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650825 | OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 383 | MedImmune LLCINDUSTRY | 11 | Jun 15, 2026 | clinicaltrials |
| NCT02987166 | HDCRT Plus Pembrolizumab in Advanced Malignancies(UVA-AM-001) | completed | Phase 1 | 21 | James Larner, MDOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05768932 | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 260 | SillaJen, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07019779 | Study of CM518D1 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 375 | BioNTech SEINDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07638371 | FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648472 | A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours. | recruiting | Phase 1 | 18 | Joint Biosciences Ltd.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05947474 | ORB-011 In Patients With Advanced Solid Tumors(ORB) | completed | Phase 1 | 55 | Orionis Biosciences IncINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06188208 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | terminated | Phase 1 | 132 | Vividion Therapeutics, Inc.INDUSTRY | 3 | Jun 12, 2026 | clinicaltrials |
| NCT07284186 | First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 155 | Plexium, Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07348653 | A Study of MG2512 Injection in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 116 | Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04266912 | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07163325 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | recruiting | Phase 1 | 48 | Epics TherapeuticsINDUSTRY | 4 | Jun 11, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 2 | Jun 10, 2026 | clinicaltrials |
| NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06975410 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Yuhan CorporationINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639047 | An Initial Evaluation of AN8025 in Solid Tumors | recruiting | Phase 1 | 91 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04890613 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | recruiting | Phase 1 | 52 | Senhwa Biosciences, Inc.INDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
| NCT06299761 | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications(STARMAP) | terminated | Phase 1 | 19 | Boundless Bio, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06422520 | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 63 | BeOne MedicinesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07238075 | ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers | recruiting | Phase 1 | 290 | Adcytherix SASINDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2026source: clinicaltrials